Entities / Company
Soligenix (United States).
company in Princeton, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 32
What's happening
Gone quiet
No new reports in 90+ days-
Soligenix and Sterling Pharma Solutions formed a partnership to transfer active ingredient manufacturing from Europe to the United States.Speculative1 report
-
Soligenix is developing products to treat rare diseases, addressing the lack of FDA-approved treatments for millions of Americans.Some support2 reports3 developments inside
-
Ellen Kim is the Principal Investigator for Soligenix trials.Speculative1 report
-
The FDA provides a development grant to Soligenix to support its work on rare disease treatments.Some support1 report
-
Soligenix announced that its drug candidate SGX945 showed efficacy similar to apremilast, leading to a stock surge reported by Benzinga.Some support1 report
-
Pfizer and Soligenix committed to making an impact in the pharmaceutical space by improving access to treatments.Some support1 report
-
Christopher J. Schaber was appointed President and CEO of Soligenix on August 14, 2025.Some support1 report
-
Soligenix was invited to present at a conference on September 2, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Soligenix (United States) this week
News at the entities that move Soligenix (United States) most-
Pfizer OperationalDave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Moves Soligenix (United States)
-
FDA Mentioned togetherGeneric medicine services are seeking approval for launch from the FDA.Moves Soligenix (United States)
Connections
The 2 strongest of 32, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.History
Events by the month they beganJune 2026
8 events- Soligenix and Sterling Pharma Solutions formed a partnership to transfer active ingredient manufacturing from Europe to the United States.
- Soligenix is developing products to treat rare diseases, addressing the lack of FDA-approved treatments for millions of Americans.
- Ellen Kim is the Principal Investigator for Soligenix trials.
- The FDA provides a development grant to Soligenix to support its work on rare disease treatments.
- Soligenix announced that its drug candidate SGX945 showed efficacy similar to apremilast, leading to a stock surge reported by Benzinga.
- Pfizer and Soligenix committed to making an impact in the pharmaceutical space by improving access to treatments.
- Christopher J. Schaber was appointed President and CEO of Soligenix on August 14, 2025.
- Soligenix was invited to present at a conference on September 2, 2025.